Alexion, AstraZeneca Rare Disease and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced positive topline results from the ...
Professor Narayanan Parameswaran's team at the Department of Physiology at Michigan State University announced the results of a study that s...
GenScript Biotech Corporation ("GenScript"), a global leader in life sciences services and products, has announced the establishment of new operations site...
a clinical-stage biotechnology company developing novel immunotherapies, announced the company will deliver poster presentations at the Society for I...
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth ...
Novo Nordisk presented an exploratory post hoc analysis from the SELECT phase 3 cardiovascular outcomes trial that showed semaglutide 2.4 mg significantly ...
November is Lung Cancer Awareness Month, and the American Lung Association (Lung Association) is kicking it off by offering free lung cancer screenings to&...
Pangea Laboratory has partnered with Unilabs, a leading European provider of clinical laboratory testing and diagnostic imaging services, to bring the Blad...
Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309 study, a randomized, control...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced new late-breaking data on its Elecsys Amyloid Plasma Panel (combination of pTau181 and ApoE4), for Alzhei...
Novartis announced that Scemblix® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients wit...
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing applica...
AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing ...
© 2025 Biopharma Boardroom. All Rights Reserved.
